Anaplastic Thyroid Cancer clinical trials

Explore recruiting anaplastic thyroid cancer clinical trials.

Recruiting anaplastic thyroid cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Anaplastic Thyroid Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

(NEOAC) NEO- and Adjuvant Targeted therapy in braf-mutated Anaplastic Cancer of the Thyroid - a prospective, non-randomized, single center, open-label phase II study.

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

IMMUNORARE5 : A national platform of 5 academic phase II trials coordinated by Lyon university hospital to assess the safety and the efficacy of the IMMUNOtherapy with Domvanalimab + Zimberelimab combination in patients with advanced RARE cancers

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and its Anti-tumour Effect in Adult Patients with CD44v6 Expressing Solid Tumours

Sweden

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Trametinib tablets 2 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with MEKINIST® (Trametinib) tablets 2 mg, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA in healthy, adult, human subjects under fasting condition.

Romania

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

Anaplastic Thyroid Cancer trials by city

Anaplastic Thyroid Cancer in Toronto Anaplastic Thyroid Cancer in Vancouver Anaplastic Thyroid Cancer in Montreal Anaplastic Thyroid Cancer in Calgary Anaplastic Thyroid Cancer in Edmonton Anaplastic Thyroid Cancer in Ottawa Anaplastic Thyroid Cancer in Winnipeg Anaplastic Thyroid Cancer in Quebec City Anaplastic Thyroid Cancer in Hamilton Anaplastic Thyroid Cancer in Kitchener Anaplastic Thyroid Cancer in London Anaplastic Thyroid Cancer in Halifax Anaplastic Thyroid Cancer in New York Anaplastic Thyroid Cancer in Los Angeles Anaplastic Thyroid Cancer in Chicago Anaplastic Thyroid Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease